We use a systems biology approach to construct protein-protein interaction networks (PPINs) for early and late stage bladder cancer. By comparing the networks of these two stages, we find that both networks showed very significantly different mechanisms. To obtain the differential network structures between cancer and noncancer PPINs, we constructed cancer PPIN and noncancer PPIN network structures for the two bladder cancer stages using microarray data from cancer cells and their adjacent noncancer cells, respectively. With their carcinogenesis relevance values (CRVs), we identified 152 and 50 significant proteins and their PPI networks (network markers) for early and late stage bladder cancer by statistical assessment. To investigate the evolution of network biomarkers in the carcinogenesis process, primary pathway analysis showed that the significant pathways of early stage bladder cancer are related to ordinary cancer mechanisms, while the ribosome pathway and spliceosome pathway are most important for late stage bladder cancer. Their only intersection is the ubiquitin mediated proteolysis pathway in the whole stage of bladder cancer. The evolution of network biomarkers from early to late stage can reveal the carcinogenesis of bladder cancer. The findings in this study are new clues specific to this study and give us a direction for targeted cancer therapy, and it should be validated in vivo or in vitro in the future.
Introduction
Cancer is the leading cause of death worldwide and its etiology occurs at the DNA, RNA, or protein level. It is a very complex disease involving cascades of spatial and temporal changes in the genetic network and metabolic pathways [1] . Various research studies have revealed that cancers are caused by multiple factors and intertwined events. Thus, in cancer therapy, it is important to dissect the diverse molecular mechanisms of cancer to identify potential cancers. Bladder cancer is amongst the 10 most common carcinomas in the USA, with 72,570 newly diagnosed cases, and it was the cause of 15,120 deaths in 2013 [2] . In particular, Kaufman et al. pointed out to it as the second most common form of cancer in 2008 [3] . In this study, we compared the early and late stages of bladder cancer to reveal additional mechanisms of bladder cancer development [4] .
Biomarker discovery of various cancers is one of the key topic areas of cancer research. It can aid investigations into carcinogenesis and novel drug designs for cancer therapy. Several bioinformatics methods have been developed and applied to compare normal tissue with cancerous tissue to determine what cancer driving genes can act as cancer biomarkers [5] [6] [7] [8] [9] [10] [11] [12] .
Genes and proteins function cooperatively to regulate common biological cell processes by coregulating each other [13] . Generally, molecular regulation and interaction proceed with time and vary in different tissues. There must exist great differences in these variations between cancer and normal tissue. Proteins mutually interact with each other in the cell, and they form the PPI networks (PPINs). Currently, a lot of the research has focused on the relationship between PPINs and cancer development. For example, analysis of the cancer-related PPINs of apoptosis has unraveled the molecular mechanisms of cancer, which has helped to identify potential novel drug targets [14] . Our previous work [14] had successfully identified the network markers of lung cancer. In this study, we modified our previous method and applied the 2 BioMed Research International novel concept to study the evolution of network markers from early to late stage bladder cancer.
Based on their PPI information and the gene expression profiles from cancer and surrounding normal samples, two PPI networks with quantitative protein association abilities for each cancer stage (early stage and late stage) and the surrounding noncancerous tissue are constructed, respectively. For each stage, the network structure and protein association abilities of the cancer and noncancer PPI networks are then compared to obtain sets of significant proteins which play important roles in the carcinogenesis process of bladder cancer.
Recently, PPI targets seem to have become a paradigm for the drug discovery of cancer therapy and precision medicine [15] . Unlike conventional drug design focusing on the inhibition of a single protein, usually an enzyme or receptor, small-molecule inhibition of direct PPIs that mediate many important biological processes is an emerging and challenging concept in drug design, especially for cancer. Extensive biological and clinical investigations have led to the identification of PPI hubs and nodes that have been critical for the acquisition and maintenance of characteristics for cell transformation in cancer. Such cancer-enabling PPIs will become promising therapeutic targets in anticancer strategies as the technologies in PPI modulator discovery and validating agents in the clinical setting advance in the future [15] .
Therefore, future research directed at PPI target discovery, PPI interface characterization, and PPI-focused chemical libraries are expected to accelerate the development of the next generation of PPI-based anticancer agents. However, the PPI networks of cancer are very complex and quite differ between early and late stage cancer. In such circumstances, we will focus on the PPI network markers with their significant carcinogenesis relevance value (CRV) to exploit the important targets and their PPI interface for early and late stage cancer characterization. Then, we will not only gain insight into the crucial common pathways involved in bladder carcinogenesis, but we will also obtain a highly promising PPI target for bladder cancers. If we are then able to develop various combined anticancer strategies to target PPIs in the early and late stage network markers in the future, it may provide emerging opportunities for anticancer therapeutic approaches.
Chen et al. developed a dynamical network biomarker (DNB) that can serve as a general early warning signal to indicate an imminent bifurcation or sudden deterioration before the critical transition occurs; that means it can identify predisease state by time series microarray data. We use different approach from their methods by sample microarray data from bladder cancer patients of different stages. Our approach could also be extended to predict some similar results as their research. That is, in this study, we simply divided the cancer into early and late stages, but there are more stages of cancer, such as stages I, II, III, and IV. If we could observe the time evolution of the cancer biomarkers at these more different stages, we could also predict the predisease state by comparing it with these cancer biomarkers at different stages [16] [17] [18] .
Materials and Methods

Overview of the Bladder Cancer Network Markers Construction Process.
A flowchart representing the construction of network biomarkers for early and late stage bladder cancer is shown in Figure 1 . We combined two data sources: (1) microarray data of bladder cancer and noncancer samples from the GEO database, while the cancer samples were divided into two groups: early stage and late stage bladder cancer. (2) The PPI database was required to construct the PPINs for bladder cancer. This data was used for PPI pool selection and the selected PPIs and the microarray data were then used for PPI network (PPIN) construction. Through regression modeling and the maximum likelihood parameter estimation method, a cancer PPIN (CPPIN) and a noncancer PPIN (NPPIN) was then obtained. The two constructed cancer and noncancer PPINs were compared to obtain the sets of significant proteins for bladder cancer based on the carcinogenesis relevance value (CRV) for each protein and the statistical assessment. The significant proteins and PPIs within these proteins were used to construct network markers at early and late stage bladder cancer.
Data Selection and Preprocessing.
The microarray gene expression dataset of bladder cancer was obtained from the NCBI gene expression omnibus (GEO) [19] . In this study, we chose GSE13507 [20] and its corresponding platform GPL6012 as our research object. The same dataset contained the early and late stage bladder cancer and noncancer samples. We only used the data derived from nonprocessed primary biopsies to avoid the discrepancies in gene expression that are intrinsic to cell culture and fixation. Therefore, the dataset utilized contained primary tumor samples of both stages from patients and adjacent nontumor tissue samples from the same cancer patients, which could be considered as control samples. To describe the extent of a patient's cancer, the cancers were classified into four stages according to their degree of invasion and migration using the TNM staging system, as defined by the American Joint Committee on Cancer (AJCC) and the International Union against Cancer (UICC). We then divided the cancer samples into two groups. In general, stages I and II described early stage cancers that have higher curability rates with medical treatment, while stages III and IV described the late stages. However, there were no corresponding noncancer samples in the surrounding area for each stage and we had only one group of surrounding noncancer samples (Table 1) . We built CPPIN and NPPIN for both early and late stage bladder cancer in this study. We obtained 37 and 106 samples for the early and late stage cancer, respectively, and 58 noncancer samples. To avoid overfitting in network construction, the maximum degree of the proteins in the PPI network should be less than the cancer/noncancer sample number [14] . In this dataset, we had a greater number of cancer and noncancer samples to overcome the sample size restriction on the size of the network. Prior to further analysis, the gene expression value, ℎ , was normalized to -transformed scores, , for each gene, i, and then the normalized expression value resulting Determination of significant proteins in two stages bladder cancers based on carcinogenesis relevance value (CRV) for each protein Figure 1 : The flowchart of constructing both stages of network marker of bladder cancer and the investigation of the carcinogenesis mechanisms. We integrate microarray data, GO database, and PPI information to construct the PPI network. These data are used for pool selection, and then the selected proteins and the microarray data are used for the contribution of protein-protein interaction network (PPIN) by maximum likelihood estimation and model order detection method, resulting in bladder cancer PPIN (CPPIN) and noncancer PPIN (NPPIN) of early and late stage. The two constructed PPINs can be used for the determination of significant proteins of tumorigenesis by the difference between two PPI matrices of two constructed PPINs. With the help of the differential PPI matrix (network) between CPPIN and NPPIN, carcinogenesis relevance value (CRV) is computed for each protein, and significant proteins in carcinogenesis are determined based on P value the CRVs of these proteins in the differential PPI matrix between CPPIN and NPPIN. These significant proteins are obtained for early and late stage bladder cancers.
had a mean = 0 and standard deviation = 1 over sample [11, 14] . The PPI data for Homo sapiens were extracted from the Biological General Repository for Interaction Database (BioGRID, downloaded in October 2012). BioGRID is an open-access archive of genetic and protein interactions that are curated from the primary biomedical literature of all major model organisms. As of September 2012, BioGRID houses more than 500,000 manually annotated interactions from more than 30 model organisms [21] . The above two databases were mined for bladder cancer and noncancer PPI networks using their corresponding microarray data. These early and late stage bladder cancer and noncancer PPI networks were then compared to obtain network markers.
Selection of Protein Pool and Identification of the ProteinProtein Interaction Networks (PPINs) for Cancerous and Noncancerous Cells.
To integrate gene expression with PPI data to construct the corresponding CPPINs and NPPINs, we set up a protein pool containing differentially expressed proteins. The gene expression values were reasonably assumed to correlate with protein expression levels. We used one-way analysis of variance (ANOVA) to analyze the expression of each protein and select for proteins with differential expression levels. This method allowed determination of significant differences between cancer and noncancer datasets. The null hypothesis (Ho) was based on the assumption that the mean protein expression levels of cancer and noncancer sets are the same. Bonferroni adjustment [22] , a type of multiple testing, was used to detect and correct proteins with discrepancy. Proteins with a value of less than 0.01 were included in the protein pool. However, if the proteins in the protein pool did not have PPI information, they were eliminated. In addition, proteins that were not already in the protein pool were included if their PPI information could determine that they had a tight relationship with proteins already in the pool. As a result, the protein pool contained proteins that had certain differences in expression levels and proteins that had tight relationships with the aforementioned proteins. In this case, the protein pool in bladder cancer consisted of 2,245 proteins in the early stage and 1,101 proteins in the late stage.
On the strength of the significant pool and PPI information, candidate PPI networks for early and late stage bladder cancer were constructed for bladder cancer and noncancer by linking the proteins that interacted with each other. In other words, the proteins that had PPI information through the pool were linked together, resulting in candidate PPI networks.
As the candidate PPIN included all possible PPIs under various environments, different organisms, and experimental conditions, the candidate PPIN needed to be further confirmed by microarray data to identify appropriate PPIs according to the biological processes that are relevant to cancer. To remove false positive PPIs from each candidate PPIN for different biological conditions, we used both a PPI model and a model order detection method to prune each candidate PPIN using the corresponding microarray data to approach the actual PPIN. Here, the PPIs of a target protein in the candidate PPIN can be depicted by the following protein association model:
where [ ] represents the expression levels of the target protein for the sample ; [ ] represents the expression level of the th protein interacting with the target protein for the sample ; denotes the association interaction ability between the target protein and its th interactive protein;
represents the number of proteins interacting with the target protein ; and [ ] represents the stochastic noise due to other factors or model uncertainty. The biological meaning of (1) is that the expression levels of the target protein are associated with the expression levels of the proteins interacting with it. Consequently, a protein association (interaction) model for each protein in the protein pool can be built as (1).
After constructing (1) for the PPI model of each protein in the candidate PPIN, we used the maximum likelihood estimation method [23] to identify the association parameters in (1) by microarray data as follows (see Supplementary Materials S.1 available online at http://dx.doi.org/10.1155/2014/ 159078):
wherêis identified using microarray data in accordance with the maximum likelihood estimation method (see Supplementary Materials).
Once the association parameters for all proteins in the candidate PPI network were identified for each protein, the significant protein associations were determined using the interaction model order detection method based on the estimated association abilities. The Akaike information criterion (AIC) [23] and Student's -test [24] were employed for both model order selection and significance determination of the protein associations in̂(see Supplementary Materials S.2).
Determination of Significant Proteins and Their Network Structures in the Carcinogenesis of Four Types of Cancers.
After values were determined using the AIC order detection and Student's -test, spurious false positive PPIŝin (2) were pruned away and only the significant PPIs that remained were refined as follows:
where ≤ denotes the number of significant PPIs of PPIN, with the target protein . In other words, a number of − (or false positives) are pruned in the PPIs of target protein . One protein by one protein (i.e., = 1, 2, . . . , for all proteins in the refined PPIN in (3)) results in the following refined PPIN:
where the interaction matrix denotes the PPIs.
If there is no PPI between proteins and or it is pruned away by AIC order detection due to insignificance in the refined PPIN then̂= 0. In general,̂=̂, but if this is BioMed Research International 5 not the case, the larger one will be chosen aŝ=̂to avoid the situation wherê̸ =̂. The above PPIN construction method was employed to construct the refined PPINs for each stage of bladder cancer (early and late) and noncancer cells. The interaction matrices of the refined PPINs in (4) for cancer and noncancer cells of both the early and late stages of bladder cancer were constructed, respectively, as follows:
where = early and late stage bladder cancer; and denote the interaction matrices of refined PPIN of the th cancer and noncancer, respectively; is the number of proteins in the refined PPIN. Therefore, the protein association model for CPPIN and NPPIN in the th stage bladder cancer and noncancer can be represented by the following equations according to (4) and (5):
where = early and late stage bladder cancer;
denote the vectors of expression levels; and ( ) and ( ) indicate the noise vectors of PPINs in the th cancer and noncancer cells, respectively.
The different matrix − of the differential PPI network between CPPIN and NPPIN in the th cancer is defined as follows:
where = early and late stage bladder cancer; denotes the protein association ability difference between CPPIN and NPPIN in the th stage bladder cancer; and the matrix indicates the difference in network structure between CPPIN and NPPIN in the th stage bladder cancer. In order to investigate carcinogenesis from the difference matrix between CPPIN and NPPIN of the th stage bladder cancer in (8) , a score, which we named the carcinogenesis relevance value (CRV), was presented to quantify the correlation of each protein in with the significance of carcinogenesis as follows [14] :
where CRV = ∑ =1 | |, and k = early and late stage bladder cancer. The CRV in (9) quantifies the differential extent of protein associations of the th protein (the absolute sum of the th row of in (8)) and the CRV can differentiate CPPIN from NPPIN in the th stage bladder cancer. In other words, the CRV in (9) could represent the network structure difference of the th protein between the cancer and noncancer networks in the th stage bladder cancer.
In order to investigate what proteins are more likely involved in the th stage bladder cancer, we needed to calculate the corresponding empirical value to determine the statistical significance of CRV . To determine the observed value of each CRV , we repeatedly permuted the network structure of the candidate PPIN of the th stage bladder cancer as a random network of the th stage bladder cancer. Each protein in the random network of the th stage bladder cancer will have its own CRV to generate a distribution of CRV for = early and late stage bladder cancer. Although there was random disarrangement of the network structure, the linkages of each protein were maintained. In other words, the proteins with which a particular protein interacted were permuted without changing the total number of protein interactions. This procedure was repeated 100,000 times and the corresponding value was calculated as the fraction of random network structure in which the CRV is at least as large as the CRV of the real network structure. According to the distributions of the CRV of the random networks, the CRV in (9) with a value of less than or equal to 0.01 was regarded as a significant CRV and the corresponding protein was determined to be a significant protein in the carcinogenesis of the th stage bladder cancer: a protein with a value greater than 0.01 was removed from the list of significant proteins in carcinogenesis (in other words, if the value of CRV was greater than 0.01, then the th protein was removed from the CRV in (9) and the remainder in the CRV with values of CRVs less than 0.01 were considered significant proteins of the th stage bladder cancer).
Based on the value of the CRVs for all proteins ( = 1, 2, . . . , ) and the two stages of bladder cancer ( = early and late stage bladder cancer), we generated two lists of significant proteins for each of the two stages according to the CRV and the statistical assessment of each significant protein in CRV in (9) . We found 152 significant proteins in early stage bladder cancer and 50 significant proteins in late stage bladder cancer. These proteins showed significant changes between the CPPIN and NPPIN in the carcinogenic process according to their corresponding stage of cancer and we suspected that these changes might play important roles in the carcinogenesis process of bladder cancer. These findings warrant further investigation.
The intersections of these significant proteins in the early and late stages of bladder cancer and their PPIs are known as the core network markers appearing in all stages of bladder cancer. In contrast, the unique significant proteins and their PPIs in each stage of bladder cancers are known as the specific network markers for each stage of cancer. We found that there were 18 significant proteins that could be classified as a core network marker in the whole carcinogenesis process of bladder cancer. We also found 134 significant proteins in the specific network marker of early stage bladder cancer and 32 significant proteins in the specific network marker of late stage bladder cancer.
Pathway Analysis.
Much valuable cellular information can be found in the known pathways, which are useful for describing most "normal" biological phenomena. All of these known pathways are the result of repeated testing and verification and the entire pathway network has given definitions for most links. Therefore, the proteins we identified to be significant in the above network markers were mapped onto the known pathway networks (e.g., the KEGG or PANTHER pathway) to investigate significant pathways with the network marker and to explore the relationships between these pathways and the carcinogenesis of bladder cancer. This approach supports the view that systems biology can help identify significant network biomarkers in both normal and cancerous pathways to their roles in the pathogenesis of cancer.
Together with comprehensive pathway databases such as the Kyoto Encyclopedia of Genes and Genomes (KEGG), we used a series of bioinformatics pathway analysis tools to identify biologically relevant pathway networks [25] . KEGG includes manually curated biological pathways that cover three main categories: systems information (e.g., human diseases and drugs), genomics information (e.g., gene catalogs and sequence similarities), and chemical information (e.g., metabolites and biochemical reactions). At present, KEGG contains 134,511 distinct pathways generated from 391 original reference pathways [26] . Therefore, to investigate the pathways involved in carcinogenesis, the bioinformatics database DAVID [27, 28] , which generates automatic outputs of the results from KEGG pathway analysis [27] , was used for the pathway analysis of significant proteins identified in network markers to determine their roles in the pathogenesis of early and late stage bladder cancer. Our methodology does not contain the pathway analysis and gene set enrichment analysis. To complete our research results, we used the NOA software to do the pathway analysis and gene set enrichment analysis on biological processes, cellular components, and molecular functions [19, 29] . (8) to investigate PPI variations of each protein in the differential PPI network due to the carcinogenesis. Finally, the carcinogenesis value (CRV) based on PPI variations is also proposed to evaluate the significance of carcinogenesis for each protein of differential PPI network. Proteins with significant CRV ( value < 0.01) are considered as significant proteins of the cancer. The significant proteins in Table 3 are these significant proteins of early and late stage bladder cancers, and these proteins and their PPIs construct the interaction network in Figure 2 . Finally, from the early to late stage bladder cancer network markers, we investigate the mechanism of carcinogenesis process with the help of databases (e.g., GO database, DAVID, and KEGG pathway database) and try to find multiple network target therapy of cancer. Unlike the conventional theoretical methods, which always give a single mathematical model for cancer network for a more detailed theoretical analysis, this study RPS7  IL7R  CDK1   RASSF1   PDE4D  MCM7  RBM10   SET   LGALS1  CSNK2A1  DCUN1D1 MTA2 TLE1   IQCB1  SMAD7   CSNK1A1  TUBB3   CDC20   GADD45GIP1   CYB5R3  IL10RA  RORA  PPP2CA  POLR2A   CYR61 KLHDC2  ZNF259 PRKAR1A  C14orf1   EFTUD2  CNN1  TNPO1 CAND1   MAD2L1 NONO  TUFM   CCND2   TUBA1A   PCGF2   PPP1CC   GAB3   AP2M1   FANCA   KPNA6   ESPL1   PIAS4  NPAT   MED14  HDAC8   SIN3B   BTK   CCND1   NCOR2   NAA10  DUS3L   PER1   PRC1   SRC   DAZAP2   STAT1  EPHA3   SNF8   RUNX1T1   CRTAP   GTF2H4   PARP1   SYNPO2  THRAP3   CCNA1  UBE2E3  PDGFB   ALDH1A3 BRP44L  MTA1 ZNF25  C21orf59   RHBDD3 PXK DSE  PHC2 TMUB1   MCOLN3 TBC1D7 PLXNA3  GJA1 UBC  PEX10  LRRC8E  PLEK  WDR74   PDGFRB   RBX1   ITM2A   PCGF5  NR4A1   PRMT5   LIG4  HOOK1  PDGFRA   RUNX3 MAGED1  RBP1   UBE2U   CGRRF1   SPTBN2 ADAMTS1 WRAP53   PELP1  PIK3R1   TOR1A   SMUG1   SKP1  COL15A1   ABCB8   CHN1   KLF9PCGF1   CNRIP1   PCYT1A   UNG  PAM   MAD2L2   EGFR  KPNA1   PJA2 SNAI2  HDGF   MED24  VPS26B   LMBRD1  DAXX   PLSCR4   WLS   STAMBPL1 TSC2  ODF2   DOCK11  DSCR3   UBLCP1  ELK1   ZNF213  MXRA7  DPYD   SLAMF1   ZNF646  GTSE1  LYN  VPS4A   IL6ST  UBE2D3   FLOT1 USP11  VEGFA   NDN  HIST2H2BE  TTYH3 PTPN6  ACTN4   CD5  ZBTB4   TYROBP   TRAF2  CD6   MDFI   STAM2  RCBTB2  ABCB1  C14orf21   RNF169   KIF2A   APBB2 IRS1  MID2   PPP2R3C SNX11  SPARCL1   DAG1  C19orf53  LIFR  MAPK3  EXOSC4  SSNA1  STK17B  FBXO8   ZNF317 TMEM180   TXNDC12  GLI2  FANCL  KHDRBS2  DLL1   TOM1L1  PACSIN1  STAT4   SMC1A   GAS7   EFNA4   EED  LIN9  DCN   SH3KBP1   COL4A6   CNOT4   WDR48 SP100   NCOA3  BACH2   MED16  USHBP1  CLEC4F  BOC  MED25   HIST1H1B   HMGB3  PER3 TRIM55  FKBP2   RNF2  FAM161B  GRK5   MED13  STARD9  MYO1G   ESRRA   ZHX1   RARB   MED31  RAI2   IFT20   GMEB2  MED17   DIXDC1   CXCL12DNM1 CD2BP2   CD247 RHOJ   MED21  RNF11   MED7   ZNF687  KAT2B CCNH  SF1   PIP4K2A  ETV4   KCNE4  TLR6  ASCC2  RBM39   XAB2  ZFYVE9   EP300   EPN1   PPARGC1A   GTF2E1   FHL1  CHEK1   RPUSD2   PPP6R1   CDKN1A CHD3 CALM1 FHL2   FANCB   MED15  LANCL1   NFIX   E2F3   Sf3a1   FNBP1   FILIP1   SVIL   CCNB1   CDK6   EDNRA   RHOA   CLTC   PSMA6  CDT1 NIF3L1  GFI1  MDC1   STAT6   SEPP1  TARBP2  RBL1   CDCA5 CSRP1  CDC6  PSMC3   C19orf40   RPL22   PRDX3   PSMA3   TUBG1   BANF1   RPS27A   ASPM   CUL5  ILK  PBK   RBMX   PTBP1   LRP1  MYC  OXSR1  UBE2O  MAGOH AP2A1   NUP153   TP53 RPL13  SORBS1 CHTF18  PCNA   PIAS1  TUBA1B  U2AF2 SYNCRIP   C6orf211 MAP1S   IMMT   ACTC1   CREBBP   TXNRD1   HSPD1   ADRM1   NEDD8   PPHLN1   TELO2  EEF1B2   CUL2   TP63   SNRPA   CBX3   MSL2   TOP2B   PMM2   IDH1  FOXO3   CRY2  DDX17   RABEP1  CSNK2A2   ANP32A   HDAC2  HDAC7  CDC25C  AATF   NR3C2   PRNP   TCERG1   ZC3H18  ISL1   MFAP4  ZNF787   NRIP1  NCOA1  AXIN1   LSAMP   DCHS1   KIAA0494  TTC1   DACT3   WDR70  SUV39H1   CBX5  UBE2M SIN3A   HNRNPA2B1   EWSR1   TNIK   RPA1   TPT1  COPS6   GULP1   RELA   TNIP2   FASN   NCOA7   RPL36AL   WDR18   YWHAZ  LMNA   MAPK1   MCM3   SKP2  RANGAP1   MBD3   BRCA1   RXRA  SMAD4   ANKRD44   GADD45A KLF10   EIF2AK2   CD2AP  EIF3I   GSK3B   SPRY1   RBBP7 FIBP MGMT   ABL1   TPX2   POLE  ATM   MCM2  LY9   EEF2K   SKAP2   GGA2   ABI3BP  PTEN   HLF  CDKN1B  MED12  KIF4A   PRDM4  NR2F1   CDAN1  PAK4  RAD21   MAP3K7  VPS33A  RPS18  PFDN6  PRKCD  GNL2 SAP18   YEATS2  RPS19BP1  ASF1A  UTP14A  RBBP4   HIST1H3D   SAMD4B   HIST1H3F   SF3B2   GPT2   SPP1 DPCD   NSUN2  POF1B  ELAVL1 TSPYL1  MMS19  RPL3  DNMT3B   ZNF521   TMEM54 MYOD1   BRD7   KLF13  PRPF19  SIRT1  SRSF9   EHMT2   SNRPD1  AR   CDC42  TFAP4   UCHL5  HDAC1  APP  SMARCC1  LEF1   TADA3  WBP4 SF3A2   ASF1B   RAN   PID1 GADD45G  PHKB   SFPQ  HSPA5  DDX5   UHRF2 ING1   ZFPM2   SRSF2   LNX1  ITCH   ACTG1 ZEB1  CD4   MEPCE   CUL3   TOR1AIP1 STOM  SRRM2  SMARCA4   SMARCC2   PFDN5  PCNP   RCC2   TAOK2  SRRM1 ESR1  PDIA4  AURKB  SLIT2  NXF1   PLK1  PUS1   G3BP1  RPS8   ECD  ADRB2  RAD50   ARNTL  CTBP1  YPEL5 AHR   VDAC2  PTGDS   SMARCE1   PTMA  NCOR1   FAM65B   TRIM24  SMARCA2   BAG1   BMP4  PRDM1   XPO5  NUMA1  DDX21  LAMP2  LMNB2   RNPS1 RPL7A   RPL5   TERF2IP   CRMP1  GLI1  HNRNPAB   CACNA1A  SPAG5   CEBPB  UTRN  RPS11  FERMT2  CAPN1   OTUB2ACD  KIF20A  HNRNPA3  PAFAH1B1  RUVBL2  EIF2C2  SUMO3   EIF6  ASNA1   ITGA4   MAPRE1   HDAC5   MTA3   GRASP   NCAPG  POLD1  SOX2   PPP1CB   PARK2  PSMD2  MYL6  FBL BIN1  SMARCAD1   HDAC4  ACTN1   PRKCSH   BUB1B  TRA2B  INPPL1  RPS14  DPYSL2   RPL6 LRRK2  STRAP  P4HB  MTOR   TERF1  GNB2L1   SLC39A7   RPL23  CUL4A  FBXO6 CENPF  PA2G4  HSPA1A   EIF3F  EIF3D CAMK1  PPP1CA HSPA4  EIF3B   CLIP3  DDX24  CUL7   CD81   BIN2   RPLP1   RPS4X  SORBS2  DSN1   EIF4A3  RUVBL1  RPS21  COPS5  THOC2   GHR VCL   ANKRD35   CALD1HNRNPF   GSN   KPNB1  CDK9   PRKCDBP  RPS6KA1   NARF AIMP2   PGM5  RB1 DSTN   HSPA8 SF3B4   BCL7C   STK24  MORC2  RPS15A  Csnk1e UBD   YWHAQ   HSP90AA1 PINK1  HNRNPM   DYNC1H1 C1QBP CDC37 AKT1S1 DES IK RIOK2   RPL17  KCTD5   EGR1   VIM  PHKG2   HNRNPA0   PAFAH1B3  HNRPDL UBA2  TOP2A  SIRT7  FOXM1 TINF2   HJURP  LONP1  PCM1  TCEB1  BCAS2   EIF3G   TPM4   PUF60  ZNF480  SHBG   TIMM13   SLC25A11  SLC25A4   PFDN2   RPS12   SMURF1  TRIP6 ACAT1   PCBP2   PSMG3  EEF1A1   STK3 TUBA1C  CRYAB  POT1   RPS26  VCAM1   POLR2H   PPIL1 RPS17 PRKAA1  CHEK2  NKX3-1   SDHB   KDM1A   PIK3R2 UBE3A   MRPS27   PPP2R1A  QARS   MRPS26  TSC22D3 GBAS   TCF3  ARID3B  SCRIB   MAP2K3  PALLD   NCL  CLIC1   ANXA7   ISG15   SPTAN1  CTNNB1   MYH11   MRPL12 NACC1 NUDT1  TUBB6   UPF1   U2AF1  DDX3X KLHL13  PAN2  LMNB1   PTK2  APIP   TPD52L2  TP53BP1   NFE2L2  SUMO2  GAPDH  RBM14   SMAD3  ZEB2  PSMD11 CHAF1A   SF3B3 SRSF1 ATN1   CEBPA  LITAF   YY1  HNRNPR   NR3C1   LRIG3  SP1  STAT3   EMD   KIF24   PIN1 TTK   Tsg101   TRIM28  TIMELESS  FLNA  BOP1   CSK   THRA  ZBTB16  STIP1   FKBP4   SMU1   CDK7  FDPS  ETS1  HNRNPUL1  HDAC11 ATXN1  Htt  SOX4   SREBF1   NOTCH1  WIPF1  CBX7  KANK2  RARA  HNRNPC  E2F1   CDH1   ROCK1  TOP1  EPB41L2  SNRPA1   DACT1  SRSF3   CDK8   USF2  ARPC3  SMAD2   PCBP1  CDK2 PSMD8  EIF4G1  IQGAP1 PLEC  UNC119  KHSRP  HNRNPA1   HNRNPH1   COPS4  ARVCF  IGBP1   TGFBR1 C19orf46   GADD45A HIST2H3C SPNS1 RBBP4  RPS19BP1  CHEK1  PYHIN1 CD2BP2  USF1  ESR2   MEN1   KAT2A   SOCS1   GTF2IRD1   PFKFB4   RELA   MED24   MTA3  CLN3 ATM  GNB2L1   PKM2   TOP2A   FUT4   LONP1   ANKRD44   COL4A6  B4GALT2  PGR  STAT5A   TPD52L2   C6orf211   HIF3A  CLNS1A  NCOA7   FANCB   KLRK1   RBPJ   FANCL CYTIP  AXIN2 EWSR1  EME2   HDAC7   RBPMS2  ADCY5   ITIH5 FANCG   ODF2 PRKDC FANCA   GRASP   LDB2  INPP1  LRCH2  DDR2 PPP1R2  ZNHIT2   ATP13A2  PAN2  POT1   NACC1   RUSC1 BRI3BP  GPT2   PPFIA3  PRKCB  SDC2   KLHL13   CNOT4   KCTD12   CYB5R3   LMNB1   NCL  PUSL1   MED13   JAK1  ME2   KLF10 CDCA5   PTEN   GANAB GFI1  PRKCSH   CCDC80   SP1  RAE1   SIN3A   LANCL1  IDH1  CAPZB  BTF3  GSK3B   MSH2  NFKB1   MYH10  FANCD2  TBC1D10B  UBE2N LIG4   CUL3   CUTC  CCNA1   CCNT1  HDAC1   MED1  KCNIP3   ANG  C16orf59   VHL   POF1B MAPK8 BIRC5   MBD2  HIC2   PPP6R1  WNT2B TLE4   SMARCC1   CDKN1A  TNS1   STAT5B ANKRD5 RWDD3   SUMO2   OSBPL10   DLL1  GIT1   GTF2F1   BUB1B   ANXA5   ZNF668   PTOV1   SKA3   SLC37A4  GTSE1  RAB11FIP4   PPP5C  TIMELESS  TCEB1 AXIN1  UTP14A   RPS16  NUP153   BIN1  AP3S1   LNX1   DDAH2   SPTBN4 TOR1AIP1 MAP2K3   MYC  PPFIA2  CPSF1  SDHA  KCTD5   CRY2  PXN  CLN8  EIF3G CAND1   NR3C1  IL10RA   CHUK   IKBKG  TUT1   NCOR1  PSMA3  IL6ST  RAF1  RASSF1 GIMAP4   NR4A1  PSMD13  TOR1A   EDNRA  NCBP1  TNF  CAMK1  CHEK2  CLIP3   CCNE1   RBM14 ANP32A   MFAP4 ANXA7   C1QBP RPS10   EIF2AK2   ZEB1  KHSRP  HIST1H2AM SOX4  PRKAR1A SIRT5  NOTCH1   TPM3   SRC   EIF6  TUBA1C  PPP1CA   STAM2  NRIP1  ATF2  TPR  DAZAP1   POLR1C  CUL4B  ZYX  RPS19   ICT1   SMARCD1   SLC25A4   STAT3  RPL36AL   TRAF6  TUBG1   BCL2   ATG7   HIF1A  FBL  TP53 TALDO1   DACT3  TLR6   AQP1   MYO1G  ACTG1   PER3  TNIK  RORA   PDE4B   WIPF1   HIST1H2BO   PLS3  KATNB1  EDIL3   PRKACA   TSHZ1  STARD9  GAS7  NDEL1  GSTM5  NINL   SGCE   SH3BP5L   PGM5   RHOJ  HLA-DMB  TNFRSF13B  TNFRSF19  GZMK  ZNF646   NPAT CCNDBP1   ZEB2  PRR12   STK32C  HOXA9   PHB   THOC4   SPRY1   CDC42   THOC5   INPPL1   FAM13B  MAPK7   MYH9   GNG10  GMEB2   ETV4   LIMS2  RBPMS  HLA-DRB4  C16orf57  UHRF2  HNRNPU  R3HDM2   CLN6   DIXDC1   FAM127B   CBX7  SETBP1  WDR70  RAI2   FAM46C   F10  THOP1  DHX15   ARPC2   Prpf8   LTBP3   JUP   DISC1  EIF3F  RPS9  UBR4   PSMA6   GTPBP2  RPS6KA1  EIF3K  NCAPG   BACH2   FOXM1  C11orf84   DARC  MEX3A   RAD23B NBR1 PSMD8  POLD1  DDX17  RPS5  RPL10L  KLHDC1  EEF2  CBX8  EPS15   MAPK3 FYCO1  RPA3 IKBKB   CAPN1  SH3KBP1  HOXA1  TBC1D7  PSMC6  EIF4G1  PSMD3  ETF1  SRGN   SPAG4   DPYSL3   PELI2 MYOT   GPRASP2  F8   ELK1   WAS   KLHDC3   CNTN2   DUS3L  ARPC3   IK   PAXIP1   PEX14   MGAT1   ABL1   DNMT1   ARPC4   TCERG1   CBL   SUMO1   EZH2   CNN1   RB1   LITAF   TUBB6 IL16  GSN SRSF1   ZAK   EPB41L2  BTBD1   PINK1   ZNF768   RBM10   RBBP7   DKK3   DOCK2  SIM2   PPP1CC   FZD7  SYNE1   TNNT1   GPKOW   HCK   PRMT5   CCDC85B GREM2   LGALS1   CNTN1  PCP4   MCRS1   TUBA1A   EMILIN1   CDC27   FZR1   FAF2   CDC23   CCL5   NR4A3  GTF2I  GSTCD   DYNLL1   UFD1L  CASKIN2   GZMM  CTSG   OLFM1   KRT19   RP9   PSMD2  PAPPA  TRAF3IP1  ASPSCR1   MYO1F  TSTA3   OTUB2  TTYH3   MORC2  CDC25A GABARAP   C6orf136   FHL2  HIST1H1B   TOP1  NCOA3 HMGA1   RPS20  PARP1  PSRC1  PDCD10   TGFB1I1   CAPNS1  SREBF1   DYNC1I2  IL7R   PCGF2   FAF1   BLK  PKIG   NFKBIB  CARHSP1   IGFBP5   HSPA1A   RPL31   IGF2BP1  RBCK1   BOC   UBXN7 KHDRBS2  EIF3BSRM  KLF13  NEDD4   HDAC9  CNOT3  SHMT2  PTP4A1   RRAS  ALG8  ISL1  RANGAP1  KLF9   PFDN6  A2M   ZFP36  TINF2   SERINC1 CRYAB   PPP3CC  GHR  RPS18   Sf3a1  KIF14  NUSAP1   STK17B  SFN  PPFIA4  GLIPR2  TBX1  MAP1SGNG7  IRS1   NR2F1  PLEC  SKP2  GSG2 IL18RAP   PFDN1   NR3C2   TSPYL1  WDR18   ESR1   TARBP2   TP53RK   PFDN2  BRCA1  RGS2   TOP2B   MPST  UBE2O   TSHZ3  ZBTB4  COL1A2 PTPN11   JAK2  HSPA4  SERPINE2  SP100  ZBTB16 XPO5  PTPN6  RTN4   CIT  POLR2H  WIBG BMPR2 ROR2 PPP1CB ASNA1 SSFA2  CSNK2A2   GAB3  KCMF1  NDUFS8  HCFC1   SLAMF1  TTC1   SPI1   ISG15   TROAP TOMM20   CATSPER1   UBE2D3  FXYD6  FAM189A2  FBXO8  SLC35E2  KIAA0494   CDT1  CRTAP  LMNB2  UNC119  NBEA  TDP1   TPT1  ZBTB20  SRPX  DDB1  ACACB   ERICH1  ZNF687  KIF2A  STAMBP   KRTCAP2  ELAVL1  MAPRE1  SMUG1  Ndc80  EED  FGFR4  CYR61  PTK2B   APP   SYNM  HMOX2 IRF8 TBP  FKBP4  CNN3  COPS2   ISOC2   SMARCE1   LIN9   TMEM223   CHST15   MMP2 HES6  EFNA3  COL3A1   FBLN5   TLE1  EPHA3  SPARC  TOP3B   GFI1B   ELANE   RUNX3  CENPF  EFNA4  COL5A1   SERPING1   C1S   C1QA   NID1   C1R   IER5L   LRRC8E   HOXA13   MID2  ZFP14   TIMM17B   STXBP6  SERPINB6  BPNT1   NMRAL1  SPARCL1 SLC7A2   ZNF200   ZNF213  ZDHHC9  ZNF713  UBLCP1  LRP6   ITGA8  SLC35C2   DSE   ZSWIM1   STYXL1   NAT14 TMEM39B  SNX11 RNF169  DOHH  DECR2   PRICKLE1  PTH1R  CCDC71   RUVBL1   PAK1  SLC5A3 SF3B14   WDR77   SFPQ  FXR2   CDK4   PPIL1   CAT  HSP90AA1   TPM2  NFIA  SORBS1  IQGAP1  GAPDH ILF2 ITGA4  STOM   DDX5   RAD23A   CA9  Mapk13  FASN   Nhp2l1   MRPS26  PUF60   PDIA4   VCAM1   HNRNPL  PPARGC1A PICALM  ITPA   HDAC4  HNRNPH1  MRPS27  PITX2   PSMC5  MAP1LC3A   HDAC6  PRKCI   DSTN   CASP8  UBAP2L RXRA  MCM6   IMMT  HNRNPM   MCM2   MBIP   ATXN1   MSN  HMGB3   ATF6B SF3A2 RYK  SF3B2  SRSF2 CHD4  TUFM   FBXO17  ACTG2  CLIC1  CCND2  RNF11  WBP4   USP7   CDK9   RBM4 SAFB  NME1 ILK   CDC5L MBP   PTBP1  SNRPA1   Gnb2   GJA1   SF3A3  ZFP106 EFTUD2 PTRF  TERF2IP  NUP188  HLA-DRB3  UHRF1  BARD1   PIAS4  NIT2  AP2A1  PRPF19  RNPS1  AKT1  RPS24  UBE2I   DDX3X  CUL5   MYL9 UBQLN4 DAXX  SCRIB  RNF123   PPP6R3 HGS   DNAJC5   SHC1  DVL2   FLNA  PTK2   ALDOA  EHMT2  EIF2C2 AZI1  U2AF2   CDCA3   CSNK2A1   EPDR1   KIF2C  DNM2   BCAS2   APBB1   TTK   SNRNP200  GATAD2A  CCNB1   TAB1  WDR5   SUCLA2   TADA2A   TADA3 HDAC5  EIF3A  LETM1  COPS5  MRPS15   SLC25A11  SNRPN   FLAD1   UPF1  YEATS2  MAPK14   AP2M1   G3BP1   HNRNPF   CSF1R   SKP1   C2orf44   HSP90AB1   SF3B4   ILF3  SMARCAD1   MLH1  ASF1B  CUL2   REM1  MYH11  MFF   HNRNPD  HNRNPA1   NEDD8   HDAC2  CLTC   AURKA   ENO1   SDHB  TRIM28 EMD  UCHL5  CDC25C   RBMX  CASP1 LAX1   TUBA1B  CUL1  NOP2  WDR83  SF3B3  XRCC6  ARNTL RPS8 RBL1 IKZF2  CTNNB1 RPS3  EIF3D   STAT4  TMEM189   CALD1   NFATC4  SSSCA1   MIF   PPP3CB   LRRK2   MAGOH   PIN1   PLXNA1   LCP2 STK3   POLA2 CALM1   ECT2   DAZAP2   SUV39H1   Tsg101   PPP1R12A   ACTB  XAB2 RUVBL2 CDK6 JAZF1   VDAC1  MED7   HSPA8 CDC20   COPS4   CREBBP   KAT5  RABAC1  BOP1   SIRT7   UBE2D4  ACAT1  POU2F1  SRSF5  ANXA1  YWHAQ  TMED10  COPS6   CIRBP  NKRF  EEF1B2 SUMO4  CHAF1A FIBP  EEF1A1  PRDX3   MED14  MRPL12   HDGF  RPS11  SAP30BP   OTUB1 RPL14  TACC3  DCTN6  RPS27A  ERAL1  EIF3L  SRRM2   ACTA2  CDK8  GRB2  HNRNPA2B1   JUN  PIK3R1  EIF1B  GADD45GIP1   CHD3   CUL7   KAT2B  ARRB1   PCM1   U2AF1   SMAD2   RPL10A   RPS4X   RPLP0  RPL7   CSNK2B   RPL5  IKZF1   OXSR1   NOP56   KPNB1   RARB   CDH11  CCNF   ZNF212   CCT5   CUL4A   CD2AP   PA2G4  MAP4K1   SGTA   SQSTM1  RPL17  EGFR PPP4C RPS26  RPS17 IPO5   RPL9   PTGDS  PABPC1  TBC1D16   SEPP1   ZNF480   RPS21  RPS27L  RPL12   GABARAPL2  MEIS1  KDM1A   RPS27  TCP1   RPL4  RPS15A   EP300 TRAF3IP3 MRPL17  CLINT1  GABARAPL1 MCM7   CALCOCO2   RPS23 FBXO25  FAU   CDK5   UBL4A RPL15   MRPL46   PTMA   SNRNP35   KPNA6 KEAP1  EBF1   VAPA   HNRNPK   THRA RPL19  STAT6  RPSA  NFE2L2  MEF2C  TNIP2  ACTC1  RPS12  SNRPD2  EIF3E   ESPL1   PIK3CD   RPA1   RAB7A   KIF24  ADRBK1  THRAP3   MED17  PPP2R1A  BCL2L1 ZFYVE16  RUVBL2  ERF  ELK1  CCT8  DCD  ALOX5  ATN1  RHOA   RPL15  XRCC2   ACTR5   ZFYVE1 XPO4TNKS STON1-GTF2A1L UBE2N RPS20SNAI2  PSMC5  ANKRD42  DAB2  RPS13 TARDBP RNF181 SRC PRPS1L1 RPL4 PLK1RPS25  GIMAP6 MAP3K11 FOXJ3 PRKACB EPC2TAF1ADDX5 TGFBR1  ICAM1 PPP1CA HSP90AB1 ZFHX4 HDAC4 UBL4AGPI MTMR9  MYO7B NOP56MURC UBE2D1 MLC1RBM11MKL1USP2 METTL3 TERF1KRT10 RPS6KA1 IPO13PAN2 ICT1 RPS8 CYR61KRT1CYP2B6 HSPA1L CALM1 RPS26C14orf166 USP51C14orf1 HBE1 BAG3 OAT APC TFG AP2M1 CASP8AP2 ADCY9 RASA3 ADAM33 YY1 ACTC1 PAAF1ACO2TMCO3 Cancer_PPI_B ACIN1 USP11ABLIM3 Cancer_PPI_A Tceb1  GZMB  NUMBL   TBP   RPF1   SYT17   KHDRBS1   PPP1CC  RPLP2  CBL   PDCD6IP   TRPC6  MFN2  NHP2L1  RNF138  ZNF804A  ZBTB25  IKBKB  SHH  FBXL5  CDY2A  CUL2  MAPK6  ZER1  PSMC6  DHX15  CASK   POU2F2   RPS23   TMEM188   GADD45G   ECM1   COPS6   SP1   STAT3   SUMO2   GNG10   RPL7   NCOA6   UBIAD1   TBL3 SYTL2   CORO1B  CNNM4  LPP  POT1  FAM134A  WASH1  LRRK2   ITGB4  DTX3   NXF1  RPS4X  HN1   PARD3B  HSPA8 PCNA  GADD45G POLD1   SF3A2   BAG3   LDLR   CUL4A   UBR5   RFWD2   TMED2  HIST2H2AC   KDELC2   C2CD2   UBASH3B  MLL4   GNG10   ITGA4   ANKRD42  PML   ECH1  KIF5B   STMN1  TAF12  USP9X  RPL7   ITSN2   WTAP  EIF4B   SSBP1   RPS27L SPG21   CUL4B   VBP1  NUP93 PSMC6   RPS21  RPS23  MDM2  TUFM   PSEN2   CLEC7A AHDC1   SERPINE2  GFPT2   COX4I1   CSNK1A1   USP2   SMAD3   HEYL   CABLES1   RORC   NEDD8  PTPRU   RPS6KA1  CAV2   SNCA   ALOX5   TPM4RAD54L  RPS12   ZNF251   MKNK2   HIST1H2BD   HNRNPH3   ILF3  AIDA  UTP14A  TRPA1  MTMR9  CLGN  SKIV2L2  LAMB1   HSPA1B   MYO15B   TMCO3   MME   TNFRSF1A  MEX3A  BPHL  RANBP2  SNRPA  ATF2  ATAD1  RPL22   DYNLRB1   SLC23A2 RAB2A IKBKG is to introduce a systems biology approach to cancer network markers based on real microarray data through the so-called reverse engineering, theoretical statistical method and data mining method in combination with big databases. These are the novelty and significance of our paper. Although we described the novelty of our systems biology model, we have validated our results by literature surveying in the research. In the future, our results will be validated by other researchers' wet-lab experiments, and we will modify our mathematical model again and again. This is the third key factor to affect the results. Although not directly, it will also have the influence on protein interaction network.
We also know that the biosystems are evolved with time. It is obvious that the early stage and late stage patients have very different symptoms; they are the key features for us to classify early and late stage bladder cancers. Since the two stage bladder cancer patients have great different symptoms, it is undoubted that the microarray data of these two stage patients will show to be quite different. As described above, the protein expression from microarray data is one of the key factors of our systems biology model to give the final CPPINs and NPPINs. And the CPPINs and NPPINs give the final network biomarkers from our systems biology model. So, the most important thing for the network biomarkers evolving is due to the evolution of microarray data at both stages of bladder cancer, which is inherent in the exhibition of cancerrelated genes due to DNA mutations in the carcinogenesis process.
Results and Discussion
Time Evolution of the Network Biomarker from Early to
Late Stage Bladder Cancer. In the first instance, we built the CPPIN and NPPIN for early and late stage bladder cancer (Figure 2) . From the differential networks between CPPIN and NPPIN of early stage and late stage bladder cancer, we then calculated the CRV of each protein in the network structure. Screening in accordance with the value of CRV, we determined the significant proteins of network markers for the two stages of bladder cancer. In the following, we will discuss the significant proteins identified in both stages and their intersection to reveal the carcinogenesis mechanisms from early to late stage bladder cancer.
Network Marker of Early and Late Stage Bladder Cancer.
After value (0.01) screening, we found that there were 152 and 50 significant proteins for early and late stage bladder cancer, respectively. In addition, their corresponding CRV values ranged between 4.1 and 158.5 and 3.4-29.9, respectively. These significant proteins and their PPIs were used to construct the network markers at early and late stage bladder cancer. The intersection network marker of both stages was a core feature that contained 18 significant proteins in carcinogenesis. We listed the 18 significant proteins and their corresponding CRV and value in both stages of bladder cancer (Table 2) . From this, we separately identified the 10 most significant proteins in early and late stage bladder cancer ( Table 3 ). The full list of the 152 and 50 significant proteins for the two stages of bladder cancer is detailed in supplementary tables (Tables S1 and S2 ).
Pathway Analysis of Early Stage Bladder Cancer.
We analyzed the pathway of early stage bladder cancer using the DAVID database. Our initial observation revealed that several cancer pathways were hit by the 152 key proteins, including 11 genes in hsa05200: pathways in cancer (Figure 3(a) ), 7 genes involved in prostate cancer, 6 genes involved in chronic myeloid leukemia, 5 genes involved in small cell lung cancer, 4 genes involved in bladder cancer, and 3 genes involved in thyroid cancer, respectively ( Table 3 ). The four genes of hsa05219 involved in bladder cancer (TP53, MDM2, RN1, and MYC) are principal genes altered in urothelial carcinoma, which is highly related to metastatic bladder cancer and are significant targets of metastatic bladder cancer therapies [30] (Figure 3(b) ). Thus, we now note that the 152 candidate proteins are not only related to bladder cancer, but also to other cancers and chronic myeloid leukemia. This would mean that common mechanisms exist between the development of the different cancers in the early stage of carcinogenesis.
Next, we proceeded to analyze the important pathways related to early stage bladder cancer (Table 4) . Firstly, the cell cycle is composed of two consecutive periods (Figure 3(c) ) characterized by DNA replication, sequential differentiation, and segregation of replicated chromosomes into two separate daughter cells. Both positive-acting and negative-acting proteins control the cells' entry and advancement through the cell cycle, which is composed of four distinct phases: G1 (Gap 1), S (synthesis), G2 (Gap 2), and M (mitosis) [31] . The G1 phase, where the cell grows in size, acts as a quality control check to determine whether the cell is ready to divide. The S phase is where the cell copies its DNA. The G2 phase involves cell checking as to whether all of its DNA has been correctly copied. The M phase is the cell division phase where the cell divides in two. Find out more about how cells prepare to divide and then share out their DNA and split in two. There are many reported discussions in regards to the cell cycle regulators and checkpoint functions involved in bladder cancer [32, 33] . Dysregulation of the cell cycle governs deviant cell proliferation in cancer. Losing the ability to control cell cycle checkpoints induces abnormal genetic instability. This may be due to the activation of tumorigenic mutations, which have been recognized in various tumors at different levels in the mitogenic signal transduction pathways: (1) ligands and receptors (receptor mutations of HER2/neu [ErB2] or the amplification of the HER2 gene), (2) downstream signal transduction networks (Raf/Ras/MAPK or PI3K-AKTmTOR), and (3) regulatory genes of the cell cycle (cyclin D1/CDK4, CDK6, and cyclin E/CDK2) [34] . Increasing evidence convincingly implicates aberrant expression of cell cycle regulators in multiple cancers. Especially the restriction point (R) is the so-called G1 checkpoint. It separates the cell cycle into a mitogen-dependent phase and a growth factor-independent phase from the commitment to enter S phase. The G1 checkpoint commitment process integrates various and complex extracellular and intracellular signal transduction into the cell nucleus. Any malfunction of the G1 checkpoint may result in uncontrolled cell proliferation or genetic instability, possibly the origin of cancer or other diseases development [35] .
The Wnt/ -catenin signaling pathways (Figure 3(d) ) are composed of many functional networks, including a bundle of signaling pathways consisting of various proteins that transduce signals from the outside of a cell through the receptors on the cell surface and into the cell interior. They contribute significantly to the developmental process, particularly to direct cell attachment and proliferation. They are one of the most powerful signaling pathways and play critical roles in human development by controlling the genetic 
(a) The proteins in the early stage bladder cancer network marker are enriched in "hsa05200:Pathways in cancer" (Rank 2 in Table 4 (e) The proteins in the early stage bladder cancer network marker are enriched in "hsa04120:Ubiquitin mediated proteolysis pathway" (Rank 13 in Table 4) Figure 3: Overview of significant pathways in network marker of early stage bladder cancer. Among these KEGG pathways via DAVID tool (Table 4) showing a significant association with specific proteins of early stage bladder cancer, these molecular pathways are entitled with P value ≤ 0.05. It shows that these pathways are identified to play an important role in the carcinogenesis mechanism of early stage bladder cancer. The proteins in network markers of early stage bladder cancer highlighted by stars show potential targets in the pathways. Due to the different naming system, the same proteins in both these tables and in our text show the different names.
programs of embryonic development and adult homeostasis [36] . Under normal conditions, the Wnt signaling pathway is critical for healthy and normal development, while in adult cells, a dysregulated Wnt signaling pathway can lead to tumorigenesis. For this purpose, cancer cells must have the ability to switch from quiescent mode to proliferation mode, as well as switching between cell proliferation and cell invasion modes. Therefore, the Wnt signaling pathway participates in each of the stages of malignant cancer development and clearly contributes to human tumor progression. Much research has been reported on the relationship between Wnt signaling pathways and urological cancers (including bladder cancer) [37, 38] .
Other pathways identified in early stage bladder cancer, such as the Notch signaling pathway, adherens junctions, the TGF-signaling pathway, ubiquitin-mediated proteolysis (a) The proteins in the late stage bladder cancer network marker are enriched in "hsa03010:Ribosome" (Rank 1 in Table 5 (c) The proteins in the early stage bladder cancer network marker are enriched in "hsa04120:Ubiquitin mediated proteolysis pathway" (Rank 3 in Table 5 ) Figure 4 : Overview of significant pathways in network marker of late stage bladder cancer. Among these KEGG pathways via DAVID tool (Table 5) showing a significant association with specific proteins of late stage bladder cancer, these molecular pathways are entitled with P value ≤ 0.05. It shows that these pathways are identified to play an important role in the carcinogenesis mechanism of late stage bladder cancer. The proteins in network markers of late stage bladder cancer highlighted by stars show potential targets in the pathways. Due to the different naming system, the same proteins in both these tables and in our text show the different names. (Figures 3(e) and 4(c) ), and the p53 signaling pathway are also associated with cancer [39] [40] [41] [42] [43] .
The NOA analysis results of the pathway and gene enrichment analysis of the early stage bladder cancer is shown in Table 4 cancer cells the upregulated ribosome biogenesis leads to an increased demand of ribosomal proteins for rRNA binding.
In this way, after ribosome biogenesis alterations, cycling cells can activate the p53 pathway to ensure cell cycle arrest or alternatively to start the apoptotic program [45] . According to our analysis, there were eight significant proteins in the late stage cancer to hit the ribosome pathway. Alternative splicing is a modification of the premessenger RNA (pre-mRNA) transcript in which internal noncoding regions of pre-mRNA (introns) are removed and then the remaining segments (exons) are joined (Figure 4(b) ). The formation of mature messenger RNA (mRNA) is subsequently capped at its 5 end and polyadenylated at its 3 end, and transported out of the nucleus to be translated into protein in the cytoplasm. Most genes use alternative splicing to generate multiple spliced transcripts. These transcripts contain various combinations of exons resulting from different mRNA variants and then are synthesized as protein isoforms. The exons are always around 50-250 base pairs, whereas introns could be as long as several thousands of base pairs. For nuclear encoded genes, splicing takes place within the nucleus after or simultaneously with transcription. Splicing is necessary for the eukaryotic messenger RNA (mRNA) before it can be translated into a correct protein. The spliceosome is a dynamic intracellular macromolecular complex of multiple proteins and ribonucleoproteins (snRNPs). For many eukaryotic introns, the spliceosome carries out the two main functions of alternative splicing. First, it recognizes the intron-exon boundaries and second it catalyzes the cut-andpaste reactions that remove introns and concatenate exons. The various spliceosomal machinery complex is formed from 5 ribonucleo-protein (RNP) subunits, termed uridine-rich (U-rich) small nuclear RNP (snRNP), transiently associated with more than 760 non-snRNPs splicing factors (RNA helicases, SR splicing factors, etc.) [46, 47] . Each spliceosomal snRNP (U1, U2, U4, U5, and U6) consists of a uridine-rich small nuclear RNA (snRNA) complexed with a set of seven proteins known as canonical Sm core or SNRP proteins. The seven Sm proteins (B/B , D1, D2, D3, E, F, and G) form a core ring structure that surrounds the RNA. All Sm proteins contain a conserved sequence motif in two segments (Sm1 and Sm2) that are responsible for the assembly and ordering of the snRNAs. They form the Sm core of the spliceosomal snRNPs [48] and process the pre-mRNA [49] . Spliceosomes not only catalyze splicing by a series of reactions, but they are also the main cellular machinery that guides splicing. Recently, scientists have found two natural compounds that can interfere with spliceosome function that also display anticancer activity in vitro and in vivo [50, 51] . Therefore, it is believable that inhibiting the spliceosome could act as a new target for anticancer drug development [52] , and it should be validated in vivo or in vitro in the future.
The NOA analysis results of the pathway and gene enrichment analysis of the late stage bladder cancer is shown in Table 5 (b): (1) Biological processes (2) Cellular components (3) Molecular functions. We saw most of the biological processes are related to cell cycle, which are different from the metabolic processes of early stage. Second, about the cellular components, there are complex evolution behaviors of the network compared with the early stage bladder cancer; there is only one intersection of these two stages that is ribonucleoprotein complex. It gives us many clues to develop evolutionary strategies for cancer target therapy. Finally, about the molecular functions, there are enzyme binding, protein binding and nucleotide binding, which are very different from the early stage bladder cancer. All the evolutionary behaviors from early to late stage bladder cancer let us reveal more hidden carcinogenesis mechanism.
Pathway Analysis of Both Early and Late Stage Bladder
Cancer. The only pathway to intersect between early and late stage bladder cancer is the ubiquitin-mediated proteolysis pathway (Table 6 ). This means it is the only housekeeping pathway for bladder cancer and that the mechanisms of early and late stage bladder cancer are completely different. We hypothesize that this may be a novel concept for target therapy. Various other researches have never built a model in accordance with the network markers at the different stages of cancer. Our results show that the network markers of early stage hit common mechanisms and fundamental pathways, such as cell cycle, cell proliferation, and Wnt signaling, among others, which are implicated in various cancers. These provide clues in that early stage bladder cancer is active in many related pathways and we can assume that it is an active process to change the cell. In contrast, in the late stage of bladder cancer, the cells were inactive and close to silence. This may mean that the cells are close to death. Should we attempt to save these cells, we should aim to focus on the ribosome and spliceosome pathways. Of course ubiquitinmediated proteolysis pathways are both active in early and late stage cancer.
Conclusions
Bladder cancer is among the 10 most common forms of carcinoma in the USA and worldwide. It is a lethal disease like other cancers and understanding the carcinogenesis mechanism can help to develop new therapeutic strategy. Identifying the PPI interface to develop small molecule inhibitors has become a new direction for targeted cancer therapy. This study, which follows from our prior work, analyzes the carcinogenesis mechanism from early to late stage bladder cancer using a network-based biomarker evolution approach. Other research studies do not distinguish network markers between these two stages of bladder cancer. Thus, our approach is advantageous in that it can provide added insight into the significant network marker evolution of the carcinogenesis process of bladder cancer. The network markers and their related pathways identified in early stage bladder cancer are mostly related to ordinary cancer mechanisms, which just show a highly active state of the early stage and cannot reveal additional novel results. All of these results should be validated in vivo or in vitro in the future. However, from the two specific and significant pathways identified in late stage bladder cancer, ribosome pathway and spliceosome pathway, we identified a novel result, which has potential to become a target for cancer therapy. The only core pathway in these two stages is the ubiquitin-mediated proteolysis pathway, which is a significant cue of carcinogenesis from early to late stage bladder cancer. Applying our method to study more cancers and more classification groups (such as stage, age, ethics, and sex) will give us further insight into the various pathogenesis mechanisms.
